Abstract：
OBJECTIVE: We aimed to evaluate the diagnostic sensitivity and specificity of the miRNA-371a-3p for the primary diagnosis of germ cell tumors (GCT) and to investigate its relationship with pathological factors and clinical stage in the Turkish population.
METHODS: In this prospective study, a total of 60 patients with GCTs, and 40 healthy male controls were examined for serum levels of miRNA-371a-3p before orchiectomy and again two weeks after surgery. The miRNA-371a-3p, alpha-fetoprotein (AFP), and beta-human chorionic gonadotropin (bHCG) levels in the preoperative and postoperative periods were compared at different clinical stages. Receiver operating characteristics curve analyses were performed to determine the sensitivity and specificity of miRNA-371a-3p. Clinical and pathological factors such as clinical stage (CS), tumor size, histology, rete testis invasion, and lymphovascular invasion, potentially impacting miRNA-371a-3p expression levels (relative quantity, RQ), were evaluated statistically.
RESULTS: The sensitivity of miR-371a-3p in GCT patients was 98.3%, and the specificity was 95% (AUC = 0.997 [95%Cl:0.99-1], p < .001). miR-371a-3p expression was not detected in two patients with teratoma. The median miR-371a-3p RQ was 489 times in GCT and 2.2 times in the Control group (p < .001). In the postoperative period, there was a significant decrease in AFP and bHCG levels in all CS-1 (p = .01) and 30% of the other CS (p = .3). Throughout this time there was a decrease of 19 times at the miR-371a-3p RQ in CS-1(p < .001) and 1.6 times in the other CS (p < .001). The miR-371a-3p RQs were correlated with tumor size and CS.
CONCLUSIONS: The miR-371a-3p seems to have higher diagnostic accuracy than classical serum tumor markers in GCT.
METHODS: In this prospective study, a total of 60 patients with GCTs, and 40 healthy male controls were examined for serum levels of miRNA-371a-3p before orchiectomy and again two weeks after surgery. The miRNA-371a-3p, alpha-fetoprotein (AFP), and beta-human chorionic gonadotropin (bHCG) levels in the preoperative and postoperative periods were compared at different clinical stages. Receiver operating characteristics curve analyses were performed to determine the sensitivity and specificity of miRNA-371a-3p. Clinical and pathological factors such as clinical stage (CS), tumor size, histology, rete testis invasion, and lymphovascular invasion, potentially impacting miRNA-371a-3p expression levels (relative quantity, RQ), were evaluated statistically.
RESULTS: The sensitivity of miR-371a-3p in GCT patients was 98.3%, and the specificity was 95% (AUC = 0.997 [95%Cl:0.99-1], p < .001). miR-371a-3p expression was not detected in two patients with teratoma. The median miR-371a-3p RQ was 489 times in GCT and 2.2 times in the Control group (p < .001). In the postoperative period, there was a significant decrease in AFP and bHCG levels in all CS-1 (p = .01) and 30% of the other CS (p = .3). Throughout this time there was a decrease of 19 times at the miR-371a-3p RQ in CS-1(p < .001) and 1.6 times in the other CS (p < .001). The miR-371a-3p RQs were correlated with tumor size and CS.
CONCLUSIONS: The miR-371a-3p seems to have higher diagnostic accuracy than classical serum tumor markers in GCT.
摘要：
目的：我们旨在评估miRNA-371a-3p对生殖细胞肿瘤（GCT）的初步诊断的敏感性和特异性，并探讨其与病理因素和临床分期的关系。
方法：在这项前瞻性研究中，共有60例GCTs患者，40名健康男性对照在睾丸切除术前和手术后两周再次检测血清miRNA-371a-3p水平。miRNA-371a-3p,甲胎蛋白（AFP），术前、术后不同临床分期的β-人绒毛膜促性腺激素(bHCG)水平进行比较。进行受试者工作特征曲线分析以确定miRNA-371a-3p的灵敏度和特异性。临床和病理因素，如临床分期（CS），肿瘤大小,组织学,睾丸侵犯，和淋巴管浸润，可能影响miRNA-371a-3p表达水平(相对数量，RQ),进行了统计评估。
结果：miR-371a-3p在GCT患者中的敏感性为98.3%，特异性为95%(AUC=0.997[95%Cl:0.99-1],p<.001)。在两名畸胎瘤患者中未检测到miR-371a-3p表达。GCT组miR-371a-3pRQ中位数为489倍，对照组为2.2倍（p<.001）。在术后期间，所有CS-1组的AFP和bHCG水平显著下降(p=.01),其他CS组的30%(p=3).在整个这段时间中，CS-1中的miR-371a-3pRQ降低了19倍（p<.001），而在其他CS中降低了1.6倍（p<.001）。miR-371a-3pRQs与肿瘤大小和CS相关。
结论：miR-371a-3p在GCT中似乎比经典血清肿瘤标志物具有更高的诊断准确性。
方法：在这项前瞻性研究中，共有60例GCTs患者，40名健康男性对照在睾丸切除术前和手术后两周再次检测血清miRNA-371a-3p水平。miRNA-371a-3p,甲胎蛋白（AFP），术前、术后不同临床分期的β-人绒毛膜促性腺激素(bHCG)水平进行比较。进行受试者工作特征曲线分析以确定miRNA-371a-3p的灵敏度和特异性。临床和病理因素，如临床分期（CS），肿瘤大小,组织学,睾丸侵犯，和淋巴管浸润，可能影响miRNA-371a-3p表达水平(相对数量，RQ),进行了统计评估。
结果：miR-371a-3p在GCT患者中的敏感性为98.3%，特异性为95%(AUC=0.997[95%Cl:0.99-1],p<.001)。在两名畸胎瘤患者中未检测到miR-371a-3p表达。GCT组miR-371a-3pRQ中位数为489倍，对照组为2.2倍（p<.001）。在术后期间，所有CS-1组的AFP和bHCG水平显著下降(p=.01),其他CS组的30%(p=3).在整个这段时间中，CS-1中的miR-371a-3pRQ降低了19倍（p<.001），而在其他CS中降低了1.6倍（p<.001）。miR-371a-3pRQs与肿瘤大小和CS相关。
结论：miR-371a-3p在GCT中似乎比经典血清肿瘤标志物具有更高的诊断准确性。
